Login to Your Account

Theratechnologies Restructures Ahead Of Phase III ThGRF Trial

By Kim Coghill

Wednesday, June 9, 2004
Theratechnologies Inc. expects to initiate a Phase III trial later this year for ThGRF, a candidate for HIV-associated lipodystrophy. At the same time, the Montreal-based company said it intends to restructure its senior management responsibilities and recruit a new chief executive officer. Luc Tanguay, the firm's current president and CEO, will assume the role of senior executive vice president and chief financial officer once a new CEO is named. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription